Back to Atlas
APotentially durableStandard research/education caution
CMP-0036
Endogenous / analogs approved
C-type natriuretic peptide (CNP-22)
Bone growth / Vascular
Supports endochondral bone growth and vasorelaxant signaling; research relevance for skeletal growth/repair
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Peptide hormone
- Primary mechanism
- NPR-B agonism with cGMP signaling
- Primary market use
- Skeletal growth research
Pharmacology
- Molecular weight (Da)
- 2,197.64
- Oral bioavailability
- N/A (peptide; not oral)
- Half-life
- ~2.6 min
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Human/Clinical
- Clinical status
- Endogenous / analogs approved
- Value-for-money score
- 3 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Native CNP is extremely short-lived; durable value usually requires analog/prodrug approaches